Lodoxamide tromethamine is a mast cell stabilizer with anti-allergic properties and can be used in studies about the treatment of asthma and allergic conjunctivitis.

In purified rat peritoneal mast cells, Lodoxamide tromethamine inhibits ionophore-induced 45Ca influx with associated histamine release[1]. Lodoxamide tromethamine significantly and dose-dependently inhibits the chemotactic response of eosinophils to fMLP and to IL-5. Lodoxamide tromethamine strongly inhibits the release of eosinophil peroxidase after IgA-dependent activation and inhibits the release of eosinophil cationic protein and eosinophil-derived neurotoxin to a lesser extent[4].

In Ascaris-sensitized anesthetized rhesus monkeys, Lodoxamide tromethamine significantly inhibits the increased respiratory frequency and decreased tidal volume induced by antigen challenge[1]. The addition of Lodoxamide tromethamine to Euro-Collins or University of Wisconsin solution increases oxygenation, decreases microvascular permeability, and increases compliance thereby decreasing lung reperfusion injury[2].